Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 121Lymphoma, Mantle-Cell 20Leukemia 14Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 11Neoplasms 10Leukemia, B-Cell 10Waldenstrom Macroglobulinemia 9Recurrence 9Lymphoma, B-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphoid 8Lymphoma 7Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Bronchiolitis Obliterans Syndrome 5Leukemia, Prolymphocytic 4Burkitt Lymphoma 4Leukemia, Hairy Cell 3Chromosome 17 deletion 3Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic, B-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoproliferative Disorders 2Immune System Diseases 2

Interventions

midostaurin 3avapritinib 2ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Ranitidine 1Interviews as Topic 1Imatinib Mesylate 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × ibrutinib × Other hematologic neoplasm × Clear all
NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Stanford University

Phase 2 Terminated
4 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡